Australia - English - Department of Health (Therapeutic Goods Administration)

ainscorp pty ltd - 47671 - epidermal osmotic dressing, non-sterile - hyalo4 skin cream is a topical preparation constituted by 0.2% hyaluronic acid as its principal component for treating and managing cutaneous irritations and lesions. to cover acute and chronic wounds {abrasions, donor sites and post-operative incisions, first and second degree burns, vascular and metabolic ulcers and pressure sores) and to provide a moist wound environment, thus protecting against abrasion, friction and desiccation.

Kenya - English - Pharmacy and Poisons Board

transagro enterprises limited p.o. box 15926-00100 nairobi - recombinant human epidermal growth factor (rhegf). - injection - recombinant human epidermal growth factor 0.075 mg - other cicatrizants

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

medifarma s.a - cloruro de sodio - cloruro de sodio....0.900g

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

medifarma s.a - dextrosa anhidra - dextrosa anhidra....5.00 g.

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

medifarma s.a - dextrosa anhidra - dextrosa anhidra....10.00 g.

Australia - English - Department of Health (Therapeutic Goods Administration)

amcla pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

amcla pty ltd -

United States - English - NLM (National Library of Medicine)

guna spa - picea mariana resin (unii: 71aov0w131) (picea mariana resin - unii:71aov0w131), semecarpus anacardium juice (unii: y0f0bu8rdu) (semecarpus anacardium juice - unii:y0f0bu8rdu), antimony trisulfide (unii: f79059a38u) (antimony cation (3+) - unii:069647rpt5), silver nitrate (unii: 95it3w8jze) (silver cation - unii:57n7b0k90a), bismuth subnitrate (unii: h19j064ba5) (bismuth cation - unii:zs9cd1i8ye), activated charcoal (unii: 2p3vwu3h10) (activated charcoal - unii:2p3vwu3h10), ipecac (unii: 62i3c8233l) ( - picea mariana resin 3 [hp_x] in 4 g - abies nigra 3x detoxification anacardium orientale 6x, 12x, 30x, 200x gas relief antimonium crudum 6x, 12x, 30x, 200x continuously hungry argentum nitricum 6x, 12x, 30x, 200x fatigue bismuthum subnitricum 6x analgesic carbo vegetalis 6x gas relief dioscorea villosa 3x analgesic dopamine 6x metabolic support epidermal growth factor 4c support tissue repair ipecacuanha 8x, 30x, 200x analgesic momordica balsamina 3x blood sugar metabolic support origanum majorana 6x, 10x, 30x antispastic robinia pseudoacacia 2x gas relief stomach 6x, 8x, 12x, 30x, 200x anti-inflammatory sympathetic nerve 3x, 6x, 12x gas relief t

European Union - English - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - carcinoma, non-small-cell lung - antineoplastic agents - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Israel - English - Ministry of Health

eli lilly israel ltd, israel - abemaciclib - film coated tablets - abemaciclib 100 mg - abemaciclib - verzenio™ (abemaciclib) is indicated:•in combination with a non-steroidal aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer.•in combination with fulvestrant for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.•as monotherapy for the treatment of adult patients with hr-positive, her2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy in the metastatic setting and prior chemotherapy in the metastatic setting including taxane in adjuvant or metastatic setting.verzenio should not be used in women after prior treatment with cyclin-dependent kinases 4 and 6 (cdk4 and cdk6) inhibitor.• verzenio in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence.in pre- or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.